DaVita
DVA
$186.10
+5.25%
DaVita Inc. is one of the largest kidney care providers in the United States, operating a network of more than 3,200 outpatient dialysis centers worldwide and treating roughly 300,000 patients annually, with approximately 35% US market share in a duopoly-style industry alongside Fresenius. The company's economics are structurally unusual for a healthcare provider: about two-thirds of US revenue comes from government payers (primarily Medicare) at regulated rates, while commercial insurers represent only around 10% of patients but generate nearly all US dialysis profits, making commercial mix and rate negotiation the true earnings engine. The current investor debate centers on whether DaVita can sustain margin expansion and free cash flow generation against a backdrop of Medicare reimbursement pressure, the looming threat of GLP-1 drugs and value-based kidney care models disrupting patient volumes, and an aggressive capital return program funded partly by debt. The stock's violent August 2026 drawdown following Q2 results, followed by a partial recovery into October, reflects a market wrestling with whether the company's cash-generative, low-multiple profile outweighs structural reimbursement and competitive risks.…
DVA
DaVita
$186.10
Related headlines
Investment Opinion: Should I buy DVA Today?
Rating: Hold with a bias toward accumulating on weakness. The core thesis is that DaVita is a cash-generative, deeply undervalued healthcare provider with a sustainable duopoly position, but structural reimbursement risks and the recent earnings-driven collapse warrant caution. The analyst consensus is 'buy' with an average target of $219.86, implying 17.4% upside, but the wide target range ($165-$270) and mixed ratings (TD Cowen upgrade vs. Truist/Barclays Hold) reflect divided conviction.
The supporting evidence is compelling: trailing PE of 11.69x and forward PE of 10.93x are well below the healthcare sector, EV/EBITDA of 9.11x is a steep discount to peers, and FCF yield of ~16.5% is exceptional. Revenue grew 5.17% YoY in Q2 2026, gross margin expanded to 32.7%, and operating margin reached 16.1%. EPS more than doubled YoY to $4.02, aided by a 25% reduction in share count. The company generates ample cash to service debt and fund buybacks, with $320.3M of Q2 FCF.
The biggest risks are reimbursement pressure (two-thirds of revenue from government payers), leverage (negative equity, 3.9x interest coverage), and the threat of GLP-1 disruption. The rating would upgrade to Buy if the stock breaks above $200 with sustained margin expansion, or if Medicare reimbursement updates prove favorable. It would downgrade to Sell if commercial mix deteriorates or if FCF declines below $1.2B annually. Relative to its own history (PE range 8.75x-18.65x) and peers, DVA is undervalued, but the discount is partly justified by structural risks.
Sign up to view all
DVA 12-Month Price Forecast
DaVita presents a classic value opportunity with significant caveats. The stock is cheap on every metric—PE, EV/EBITDA, FCF yield—and generates robust cash flow that supports buybacks and debt reduction. However, the structural risks of government payer concentration, leverage, and emerging competitive threats justify a discount. The August selloff likely overshot to the downside, but the lack of a clear catalyst for multiple re-rating keeps the stance neutral. I would upgrade to bullish if the stock breaks above $200 with volume and margin expansion continues, or if Medicare reimbursement updates are favorable. I would downgrade to bearish if commercial mix deteriorates or if FCF falls below $1.2B.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on DaVita's 12-month outlook, with a consensus price target around $219.86 and implied upside of +18.1% versus the current price.
Average Target
$219.86
0 analysts
Implied Upside
+18.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$165 - $270
Analyst target range
Seven analysts cover DaVita with a consensus recommendation of "buy" (mean rating 2.375 on a scale where lower is more bullish), and an average target price of $219.86, implying roughly +17.4% upside from the current $187.31. The consensus leans moderately bullish, but the distribution is mixed: recent actions include TD Cowen upgrading to Buy from Hold on August 7, 2026, UBS maintaining Buy, and Truist and Barclays holding at Hold/Equal Weight, indicating conviction is concentrated rather than broad. Consensus estimates call for average EPS of $18.12 (range $17.53–$18.93) on average revenue of $15.89 billion (range $15.50–$16.45 billion), which underpins the forward PE of 10.93x.
The target range of $165 to $270 is wide — a 64% spread from low to high — signaling meaningful uncertainty. The $270 high target implies roughly +44% upside and likely assumes multiple re-rating toward the mid-teens EV/EBITDA alongside sustained margin expansion, buyback-driven EPS accretion, and resolution of reimbursement fears; the $165 low target implies about -12% downside and likely prices in commercial mix deterioration, Medicare rate pressure, or a re-test of the August lows near $173. The August 7 TD Cowen upgrade to Buy came immediately after the post-earnings collapse, suggesting at least one analyst viewed the selloff as overdone, while the persistence of Hold/Equal Weight ratings from Truist and Barclays reflects lingering caution on structural risks. With only seven analysts and a wide dispersion, price discovery is less efficient than for large-cap peers, and the stock's 7.24 short ratio indicates elevated short interest that could amplify moves in either direction.
Bulls vs Bears: DVA Investment Factors
The bull case rests on deep value (11.7x PE, 9.1x EV/EBITDA), strong free cash flow ($1.61B), margin expansion, and aggressive buybacks that have driven EPS growth despite modest revenue gains. The bear case centers on structural reimbursement risk, leverage, and the August earnings collapse that exposed how fragile sentiment is. Currently, the evidence is balanced but leans slightly bearish in the near term due to technical damage and unresolved reimbursement overhangs. The single most important tension is whether DaVita can sustain commercial pricing and margin expansion in the face of Medicare pressure and emerging GLP-1 disruption—if margins hold, the stock is cheap; if they crack, the low multiple is a value trap.
Bullish
- Deep value on cash flow: DVA trades at 11.69x trailing PE and 10.93x forward PE, with EV/EBITDA of 9.11x and a free cash flow yield of roughly 16.5% ($1.61B FCF on a $9.78B market cap). These multiples are well below healthcare provider peers (mid-teens EV/EBITDA) and imply the market is pricing in significant pessimism.
- Margin expansion and EPS growth: Q2 2026 gross margin expanded to 32.7% from 31.4% in Q1, operating margin rose to 16.1% from 14.1%, and diluted EPS jumped to $4.02 from $2.87 sequentially. The EPS surge was amplified by a 25% reduction in diluted shares (88.1M to 66.1M) over three quarters, showcasing aggressive buyback accretion.
- Strong free cash flow and capital returns: Trailing FCF is $1.61B, and Q2 alone generated $320.3M of FCF after capex. The company repurchased $364.4M of stock and repaid $157.8M of debt in Q2, demonstrating robust cash generation that supports both deleveraging and shareholder returns.
- Analyst upside and buy consensus: The consensus rating is 'buy' (mean 2.375) with an average target of $219.86, implying 17.4% upside from $187.31. TD Cowen upgraded to Buy on August 7, 2026, right after the post-earnings selloff, suggesting some analysts view the drop as overdone.
Bearish
- August earnings collapse signals fragility: The stock plunged ~21% in two days (from $227.99 on Aug 4 to $180.67 on Aug 6) on heavy volume, likely triggered by Q2 earnings. This distribution event underscores how quickly sentiment can reverse and leaves a massive overhead gap that has yet to be repaired.
- Reimbursement and payer concentration risk: About two-thirds of US revenue comes from government payers (primarily Medicare) at regulated rates, while commercial insurers represent only ~10% of patients but nearly all profits. Any adverse Medicare rate update or commercial mix deterioration would disproportionately hit earnings.
- Aggressive leverage and negative equity: Debt-to-equity is -23.12 due to negative book equity from years of buybacks, and total debt-to-capitalization is 1.076. Interest coverage is only ~3.9x, leaving limited cushion if cash flow declines. The current ratio of 1.29 is adequate but not strong.
- Structural threats from GLP-1s and value-based care: The emergence of GLP-1 drugs and value-based kidney care models could disrupt patient volumes and shift reimbursement dynamics. While not yet material in the numbers, these threats create a persistent overhang on the stock's multiple.
DVA Technical Analysis
DaVita is in a powerful but volatile uptrend: the stock is up 49.55% over the past year and 63.58% year-to-date, massively outperforming the S&P 500's 15.53% and 11.93% respective gains, with relative strength of +34.02% over one year and +51.65% YTD. At the current price of $187.31, the stock sits at roughly 60% of its 52-week range (52-week low of $101.00, high of $247.49), meaning it has surrendered a substantial portion of its highs but remains far above its base — a positioning that signals a damaged but not broken uptrend rather than a falling knife. The 27.86% max drawdown underscores how sharply the stock can reverse when sentiment shifts.
Short-term momentum has decelerated sharply and diverges from the longer-term trend. The stock is down 3.38% over the past month and down 20.96% over three months, versus a +1.22% one-month and +2.69% three-month gain for SPY, producing relative strength of -4.60% and -23.65% over those windows. The critical event was the early-August gap: the stock fell from $227.99 on August 4 to $188.69 on August 5 and $180.67 on August 6, a roughly 21% two-day collapse on heavy volume that likely coincided with Q2 earnings released August 4 — a classic distribution event. Since then, price has chopped in a $173–$194 range, with a recent bounce to $189.16 on October 15 and $187.31 on October 16 suggesting stabilization, though the 6-month change of +26.64% still shows the intermediate trend remains positive.
Key technical levels are well defined. Resistance sits at the $194–$200 zone (the September 16 high of $193.86 and the pre-crash consolidation area), with the ultimate ceiling at the $247.49 52-week high; a decisive breakout above $200 would signal the August gap is being repaired and could re-open the path toward the highs. Support rests at the $173.82 August 21 low, with the $165 analyst low target and the $101.00 52-week low as deeper floors; a breakdown below $173 would confirm a lower-high/lower-low structure and likely target the $160s. With a beta of just 0.795, DaVita is roughly 20% less volatile than the market on a fundamental basis, but the 27.86% drawdown and the August gap show that idiosyncratic event risk — not market beta — is the dominant risk here, which argues for position sizing based on event exposure rather than index correlation.
Beta
0.80
0.80x market volatility
Max Drawdown
-27.9%
Largest decline past year
52-Week Range
$101-$247
Price range past year
Annual Return
+44.2%
Cumulative gain past year
| Period | DVA Return | S&P 500 |
|---|---|---|
| 1m | +1.3% | -1.2% |
| 3m | -21.0% | +3.4% |
| 6m | +22.6% | +7.0% |
| 1y | +44.2% | +14.4% |
| ytd | +62.5% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DVA Fundamental Analysis
Revenue is growing steadily but at a modest pace. Q2 2026 revenue was $3.554 billion, up 5.17% year-over-year from $3.380 billion in Q2 2025, and the sequential trajectory has been consistent: $3.224 billion (Q1 2025), $3.380 billion (Q2 2025), $3.420 billion (Q3 2025), $3.620 billion (Q4 2025), $3.416 billion (Q1 2026), and $3.554 billion (Q2 2026). The US dialysis and related lab services segment accounts for essentially all reported revenue at $10.12 billion, so growth is a function of treatment volume, commercial rate increases, and Medicare rate updates rather than new business lines. The mid-single-digit growth rate is respectable for a mature provider but implies the investment case rests on margin and cash flow rather than top-line acceleration.
Profitability is solid and improving. Q2 2026 net income was $265.4 million (net margin 7.47%) on gross profit of $1.162 billion (32.7% gross margin), with operating income of $570.8 million (16.1% operating margin) and EBITDA of $753.1 million (21.2% EBITDA margin). The trend is clearly upward: net income rose from $197.5 million in Q1 2026 and $234.2 million in Q4 2025, while gross margin expanded from 31.4% in Q1 2026 to 32.7% in Q2 2026 and operating margin from 14.1% to 16.1%. Diluted EPS jumped to $4.02 in Q2 2026 from $2.87 in Q1 2026 and $2.45 in Q4 2025, aided by share count reduction from 88.1 million diluted shares in Q4 2025 to 66.1 million in Q2 2026. The 27.0% gross margin and 14.7% operating margin reported in the valuation snapshot are consistent with a capital-intensive, labor-heavy facility business where scale and commercial mix drive profitability.
Balance sheet and cash flow are the crux of the story. Trailing free cash flow is $1.61 billion, and Q2 2026 alone generated $490.1 million of operating cash flow against $169.8 million of capex for $320.3 million of FCF, while the company repurchased $364.4 million of stock and repaid $157.8 million of debt in the quarter. However, the balance sheet is aggressively levered: debt-to-equity is reported at -23.12 (reflecting negative book equity from years of buybacks), total debt-to-capitalization is 1.076, and the current ratio is 1.29 with cash of $751.9 million. ROE of -114.7% and negative book value mean traditional leverage metrics are distorted; the more meaningful gauge is interest coverage of roughly 3.9x and FCF yield of about 16.5% on the $9.78 billion market cap, which shows the company generates ample cash to service debt and fund buybacks, but leaves limited cushion if reimbursement or commercial pricing deteriorates.
Quarterly Revenue
$3.6B
2026-06
Revenue YoY Growth
+5.2%
YoY Comparison
Gross Margin
32.7%
Latest Quarter
Free Cash Flow
$1.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DVA Overvalued?
Because DaVita is profitable — Q2 2026 net income of $265.4 million and trailing EPS of $4.02 diluted — the PE ratio is the appropriate primary metric, and it paints a cheap picture: trailing PE of 11.69x versus a forward PE of 10.93x. The modest gap between trailing and forward multiples implies the market expects only modest earnings growth, consistent with a mature, regulated provider; notably, the forward PE of 10.93x on an estimated EPS average of $18.12 is far below the trailing figure, suggesting either the trailing EPS figure in the data is distorted by one-time items or the consensus forward estimate embeds substantial earnings expansion. The negative PEG ratio of -0.99 is not meaningful given the sign distortion, and the negative PB of -15.02 simply reflects negative book equity from buybacks rather than distress.
On peer comparison, DaVita trades at a steep discount to the broader healthcare sector. Its PS ratio of 0.72x, EV/Sales of 1.90x, and EV/EBITDA of 9.11x are low absolute multiples for a business with 21% EBITDA margins and $1.6 billion of free cash flow; the PCF ratio of 5.19x is exceptionally low. Against a healthcare provider peer set that typically trades in the mid-teens EV/EBITDA and 1.5–3.0x EV/Sales, DaVita's 9.1x EV/EBITDA and 1.9x EV/Sales represent a meaningful discount, which is arguably justified by its government-payer concentration, leverage, and regulatory overhang, but the gap looks wide relative to the company's cash generation.
Historically, DaVita's own valuation band has compressed. Its PE ratio was 13.57x at Q2 2026, 13.11x at Q1 2026, 11.32x at Q4 2025, and 15.89x at Q3 2025, versus 8.75x–18.65x across 2023–2025, while its PS ratio of 4.06x at Q2 2026 compares with 2.70x–4.21x over the past three years. The current trailing PE of 11.69x sits in the lower-middle of its historical range, suggesting the market is pricing in caution rather than optimism — consistent with the August earnings-driven selloff — and leaving room for re-rating if margin expansion and buyback-driven EPS growth continue.
PE
11.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~19x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.1x
Enterprise Value Multiple
Investment Risk Disclosure
DaVita's financial risks are substantial. The company carries a debt-to-equity ratio of -23.12 (reflecting negative book equity from buybacks) and total debt-to-capitalization of 1.076, with interest coverage of only ~3.9x. While trailing FCF of $1.61B comfortably covers interest expense of ~$146M per quarter, the aggressive capital return program ($364.4M buyback in Q2 alone) leaves limited cushion if cash flow deteriorates. Additionally, revenue growth is modest at 5.17% YoY, and any margin compression could quickly erode the EPS growth that buybacks have amplified.
Market and competitive risks are significant. DVA trades at a discount to peers (9.1x EV/EBITDA vs. mid-teens), but this discount is arguably justified by its government-payer concentration and regulatory overhang. The stock's beta of 0.795 suggests lower market correlation, but idiosyncratic event risk is high—the August 2026 earnings collapse (-21% in two days) demonstrates how quickly sentiment can shift. Competitive threats from GLP-1 drugs and value-based care models could disrupt patient volumes, while Medicare reimbursement pressure remains a perennial risk. Recent news is sparse, but the market's reaction to Q2 results suggests investors are focused on any sign of commercial mix weakness.
The worst-case scenario would involve a combination of Medicare rate cuts, commercial payer mix deterioration, and a failed margin expansion story. In that scenario, the stock could retest its 52-week low of $101.00, representing a 46% decline from the current $187.31. The analyst low target of $165 implies a more moderate -12% downside, but the 27.86% max drawdown over the past year shows how severe a selloff can be. A break below the August low of $173.82 would likely trigger further selling toward the $160s, and a failure to hold $165 could open the door to the $101 low.
FAQ
The key risks are: 1) Reimbursement risk—two-thirds of revenue comes from government payers, and any Medicare rate cuts would hit margins; 2) Leverage—negative equity and 3.9x interest coverage limit financial flexibility; 3) Competitive disruption—GLP-1 drugs and value-based care models could reduce dialysis volumes; 4) Event risk—the August 2026 earnings collapse (-21% in two days) shows how quickly sentiment can reverse. These risks are ranked from most to least severe, with reimbursement being the most critical.
Our 12-month forecast has a base case (55% probability) of $200-$230, aligned with the analyst average target of $219.86, assuming stable margins and mid-single-digit revenue growth. The bull case (25%) targets $240-$270, driven by multiple re-rating and favorable reimbursement. The bear case (20%) targets $150-$170, reflecting margin compression and commercial mix deterioration. The most likely scenario is the base case, with the key assumption that Medicare reimbursement remains stable and buybacks continue to support EPS.
DVA appears undervalued on most metrics. Its trailing PE of 11.69x and forward PE of 10.93x are well below the healthcare sector average, and EV/EBITDA of 9.11x is a steep discount to peers (mid-teens). The FCF yield of ~16.5% is exceptionally high. However, the discount is partly justified by structural risks such as government payer concentration and leverage. Relative to its own historical PE range (8.75x-18.65x), the stock is in the lower-middle, suggesting the market is pricing in caution rather than optimism.
DVA is a good buy for value-oriented investors with a medium-to-long-term horizon, given its deep discount (11.7x PE, 9.1x EV/EBITDA) and strong FCF yield of ~16.5%. The analyst consensus is 'buy' with a target of $219.86, implying 17.4% upside. However, the stock carries significant risks, including reimbursement pressure and leverage, and the August earnings collapse shows it can be volatile. It is best suited for investors who can tolerate event risk and believe margins will hold.
DVA is more suitable for medium-to-long-term investment (at least 1-2 years) given its value characteristics and cash flow generation. The stock's beta of 0.795 suggests lower market volatility, but idiosyncratic event risk is high, as seen in the August 2026 selloff. Short-term trading is risky due to earnings-driven gaps and low analyst coverage (7 analysts). A minimum holding period of 12-18 months is recommended to allow for potential multiple re-rating and to ride out reimbursement-related volatility.